Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TNF Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for TNF Pharmaceuticals, Inc.

TNFA

TNF Pharmaceuticals, Inc.

About TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals is a clinical-stage biotech focused on extending healthy lifespan through developing therapies targeting autoimmune and age-related diseases. Its key platforms include Isomyosamine, an oral immunometabolic drug for autoimmune conditions and frailty, and Supera-CBD, a synthetic analog of CBD for neurological and pain disorders. The company advances innovative, well-defined drug candidates with potential safety advantages, aiming for regulatory approval and strategic commercialization.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from TNF Pharmaceuticals, Inc.

1
1
TNF Pharmaceuticals, Inc. Q/C Technologies Reports $1.24 Million Net Loss in Q1 2026, Shifts Focus to Blockchain Infrastructure

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
TNF Pharmaceuticals, Inc. Q/C Technologies Reports 45% Decrease in Net Loss, Focuses on Laser-Based Computing Technology

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
TNF Pharmaceuticals, Inc. Q/C Technologies Reports Improved Financials and Strategic Shift to Blockchain Infrastructure

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TNF Pharmaceuticals, Inc. TNF Pharmaceuticals Reports Q2 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TNF Pharmaceuticals, Inc. TNF Pharmaceuticals Reports $1.1M Net Loss and Faces Liquidity Challenges in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TNF Pharmaceuticals, Inc. TNF Pharmaceuticals Reports $27.2 Million Net Loss for 2024, Undergoes Significant Corporate Changes

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TNF Pharmaceuticals, Inc. TNF Pharmaceuticals Reports Net Loss, Increased Assets, and Strategic Changes in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments